Search

Background and Aim: Polycystic ovary syndrome is a highly prevalent and important cause of infertility. This complication demonstrates relationships with obesity, increased androgen production, and insulin resistance. The typical pattern of dyslipidemia in women with PCOS is a decrease in high-density lipoprotein and an increase in triglycerides. On the other hand, fat people are at a higher risk of hyperandrogenism, insulin resistance, hypercholesterolemia, hypertriglyceridemia, and infertility compared to ordinary people. Methods: In this cross-sectional study, 150 patients under 40 years suffering from PCOS based on the Rotterdam criteria, who were candidates for in vitro fertilization (IVF), were examined at Yas Hospital (Tehran, Iran) from April to September 2022. In addition to demographic information, lipid profile, body mass index, obstetric, fasting blood sugar (FBS), beta HCG (negative or positive), and ultrasound were also checked and pregnancy status was checked six weeks later. Results: The rate of clinical and chemical pregnancy in women with a normal BMI was about two times that of women with a BMI above 25 kg/m2. In addition, the pregnancy rate in women with dyslipidemia was significantly lower than that in ordinary women. The amount of FBS was substantially lower in people with positive pregnancies. Conclusion: The probability of pregnancy in PCOS women with a BMI is higher than normal women, and dyslipidemia is lower than that in ordinary people. Therefore, enhancing BMI and dyslipidemia in these women before starting infertility treatment is recommended.

Background: Date Palm Pollen (DPP) has traditionally been used to increase sexual ability and fertility. In several animal studies, the effects of this herbal medicine on testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) have been shown.Objectives: This study was conducted to evaluate the effects of this drug on the serum levels of testosterone, LH, and FSH in men.Methods: In this semi-experimental study, a daily dose of 6 g dry powder of DPP in two separate doses (3 g every 12 hours) was administered orally to 30 eligible men for three months. The changes in mean serum levels of hormones were statistically evaluated after the intervention compared to the baseline. The serum concentration of the hormones was assayed through the enzyme-linked immunosorbent assay method. Data were analyzed using paired t-tests.Results: After recruitment, among 30 participants, 24 men received the intervention and finally were analyzed. The mean (SD) age and body mass index of participants were 32.85 (0.43) years and 26.5 (0.5) kg/m2. DPP significantly increased the serum levels of testosterone (from 5.31 ± 0.40 ng/mlto 6.88 ± 0.71 ng/ml; p=0.019) but did not affect the serum levels of FSH (from 4.31 ± 0.50 IU/L to 4.70 ± 0.61 IU/L; p=0.511). It also significantly decreased the serum levels of LH (from 5.65 ± 0.81 IU/L to 4.52 ± 0.90 IU/L; p= 0.033). There were no reported side effects.Conclusion: The results indicated an increasing effect of DPP on serum testosterone and decreasing effect on serum LH. However, DPP had no significant effect on FSH serum levels.